Fennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) CEO Rosty Raykov sold 44,300 shares of the business's stock in a transaction dated Friday, April 5th. The stock was sold at an average price of $10.75, for a total value of $476,225.00. Following the completion of the sale, the chief executive officer now directly owns 187,471 shares of the company's stock, valued at approximately $2,015,313.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.
Rosty Raykov also recently made the following trade(s):
- On Wednesday, April 3rd, Rosty Raykov sold 40,584 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $10.78, for a total value of $437,495.52.
Fennec Pharmaceuticals Stock Performance
Fennec Pharmaceuticals stock opened at $10.69 on Friday. The business's 50-day simple moving average is $10.01 and its 200-day simple moving average is $9.14. The firm has a market capitalization of $289.06 million, a PE ratio of -17.52 and a beta of 0.38. Fennec Pharmaceuticals Inc has a 52 week low of $6.30 and a 52 week high of $11.92.
Hedge Funds Weigh In On Fennec Pharmaceuticals
A number of institutional investors have recently made changes to their positions in FENC. UBS Group AG increased its stake in shares of Fennec Pharmaceuticals by 4,742.2% in the third quarter. UBS Group AG now owns 3,099 shares of the company's stock worth $26,000 after purchasing an additional 3,035 shares during the period. Royal Bank of Canada increased its stake in shares of Fennec Pharmaceuticals by 650.5% in the second quarter. Royal Bank of Canada now owns 3,182 shares of the company's stock worth $28,000 after purchasing an additional 2,758 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Fennec Pharmaceuticals by 107.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,048 shares of the company's stock worth $34,000 after purchasing an additional 1,578 shares during the period. BNP Paribas Arbitrage SNC increased its stake in shares of Fennec Pharmaceuticals by 2,777.1% in the second quarter. BNP Paribas Arbitrage SNC now owns 4,891 shares of the company's stock worth $43,000 after purchasing an additional 4,721 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in Fennec Pharmaceuticals during the third quarter valued at about $50,000. 55.51% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Elon’s New A.I. Device is About to Shock the World
From InvestorPlace | Ad
Using this device you see above…
Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in…
“The next step in human evolution.”
Click here to see the details because there’s a lot of money at stake.
A number of analysts have weighed in on FENC shares. HC Wainwright boosted their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Thursday. Craig Hallum boosted their price target on Fennec Pharmaceuticals from $17.00 to $18.00 and gave the stock a "buy" rating in a research report on Monday, March 18th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $16.00 price target on shares of Fennec Pharmaceuticals in a research report on Monday, March 18th.
Check Out Our Latest Stock Report on FENC
About Fennec Pharmaceuticals
(
Get Free Report)
Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
